<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2015.52016</article-id><article-id pub-id-type="publisher-id">ACM-15441</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20150200000_90760539.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  MPV、FIB、UA水平与冠心病的关系及研究进展
  Progress and Relationship between Level of MPV, FIB, UA and Coronary Heart Disease
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>贾</surname><given-names>梅</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>志跃</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杜</surname><given-names>秀丽</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>内蒙古医科大学病理学与病理生理学教研室，内蒙古 呼和浩特</addr-line></aff><aff id="aff2"><addr-line>内蒙古医科大学病理生理学专业，内蒙古 呼和浩特</addr-line></aff><aff id="aff4"><addr-line>内蒙古巴彦淖尔市医院，内蒙古 巴彦淖尔</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>30</day><month>04</month><year>2015</year></pub-date><volume>05</volume><issue>02</issue><fpage>89</fpage><lpage>94</lpage><history><date date-type="received"><day>Nov.</day>	<month>25th,</month>	<year>2014</year></date><date date-type="rev-recd"><day>Dec.</day>	<month>11th,</month>	<year>2014</year>	</date><date date-type="accepted"><day>Dec.</day>	<month>20th,</month>	<year>2014</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   冠心病严重威胁人类健康，它是多种因素导致的疾病，除了以往的主要危险因素外，近年来大量研究发现，血小板平均体积、血浆纤维蛋白原、血尿酸与冠心病的发生、发展及预后密切相关。MPV是血小板活化的生物学指标，FIB是重要的凝血因子，血尿酸则是重要的炎性因子，通过不同的机制促进血栓形成，参与动脉粥样硬化的发生、发展。联合检测以上三项指标，有可能提高其对冠心病的早期诊断及冠脉病变严重程度的预测价值。本文就血小板平均体积、血浆纤维蛋白原、血尿酸与冠心病的关系及研究进展做一综述。 Coronary heart disease is a serious threat to human health, it is a disease caused by a variety of factors, in addition to main risk factors, in recent years, a large number of studies have found that mean platelet volume, fibrinogen and uric acid is closely related to the occurrence, development and prognosis of coronary heart disease. Mean platelet volume is a biological indicator of platelet activation, fibrinogen is an important clotting factor, uric acid is an important inflammatory cyto-kines, through different mechanisms result in thrombosis, and participate in the occurrence and development of atherosclerosis. Combined detection of three indicators, it is possible to improve its predictive value of early diagnosis and the severity of coronary lesions in coronary heart disease. This paper reviews the progress and relationship between level of mean platelet volume, fibrinogen, uric acid and coronary heart disease.
    
  
 
</p></abstract><kwd-group><kwd>冠心病，血小板平均体积，纤维蛋白原，尿酸，预测, Coronary Heart Disease</kwd><kwd> Mean Platelet Volume</kwd><kwd> Fibrinogen</kwd><kwd> Uric Acid</kwd><kwd> Prediction</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>MPV、FIB、UA水平与冠心病的关系 及研究进展<sup> </sup></title><p>贾梅<sup>1,2</sup>，刘志跃<sup>3*</sup>，杜秀丽<sup>2</sup></p><p><sup>1</sup>内蒙古医科大学病理生理学专业，内蒙古 呼和浩特</p><p><sup>2</sup>内蒙古巴彦淖尔市医院，内蒙古 巴彦淖尔</p><p><sup>3</sup>内蒙古医科大学病理学与病理生理学教研室，内蒙古 呼和浩特</p><p>Email: jiameimei2000@126.com, <sup>*</sup>liuleap@163.com</p><p>收稿日期：2015年5月25日；录用日期：2015年6月15日；发布日期：2015年6月19日</p><disp-formula id="hanspub.15441-formula5284"><graphic xlink:href="http://html.hanspub.org/file/6-1570131x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>冠心病严重威胁人类健康，它是多种因素导致的疾病，除了以往的主要危险因素外，近年来大量研究发现，血小板平均体积、血浆纤维蛋白原、血尿酸与冠心病的发生、发展及预后密切相关。MPV是血小板活化的生物学指标，FIB是重要的凝血因子，血尿酸则是重要的炎性因子，通过不同的机制促进血栓形成，参与动脉粥样硬化的发生、发展。联合检测以上三项指标，有可能提高其对冠心病的早期诊断及冠脉病变严重程度的预测价值。本文就血小板平均体积、血浆纤维蛋白原、血尿酸与冠心病的关系及研究进展做一综述。</p><p>关键词 :冠心病，血小板平均体积，纤维蛋白原，尿酸，预测</p><disp-formula id="hanspub.15441-formula5285"><graphic xlink:href="http://html.hanspub.org/file/6-1570131x7_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s3"><title>1. 引言</title><p>冠心病严重威胁人类健康。近年来，冠心病在我国的发病率、死亡率呈逐年升高的趋势，其发病过程包括脂质代谢紊乱、血栓形成和血管壁的慢性炎症。冠心病是多因素导致的疾患，除了主要的危险因素年龄、性别、吸烟、高血压、糖脂代谢紊乱、肥胖、遗传史外，近年来新发现的危险因素如血小板平均体积(mean platelet volume, MPV)、血浆纤维蛋白原(fibrinogen, FIB)、血尿酸(uric acid, UA)与冠心病的发生、发展及预后有密切关系。对于MPV、FIB、UA与冠心病之间的确切相关性，以及这些重要参与环节自身之间的相关性，国内外尚存在一定争议。现将MPV、FIB、UA与冠心病之间的关系及研究进展做一综述。</p></sec><sec id="s4"><title>2. MPV与冠心病</title><p>MPV是血小板活化的生物学指标，代表外周血中单个血小板的平均体积，它反映血小板的成熟情况及骨髓中巨核细胞的代谢及增生情况，体积较大的血小板代谢能力和酶活性更强，含有较高的糖原、蛋白质、酶及血小板颗粒，可以产生更多的血管活性物质及凝血因子，对血栓的形成有更强的促进作用；大于12fL的血小板含有较多致密颗粒，可以释放5-羟色胺及B-血栓蛋白等，增强血小板之间的聚集和黏附力，使凝血酶和胶原的聚集反应增强，促进血栓形成[<xref ref-type="bibr" rid="hanspub.15441-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.15441-ref2">2</xref>] ，而血小板活化又是形成血栓的关键，可导致急性冠脉综合征等动脉血管闭塞事件的发生[<xref ref-type="bibr" rid="hanspub.15441-ref3">3</xref>] 。已有大量研究报道，MPV升高(&gt;11.01fL)，缺血性心脏病发生死亡的风险较高，其危害与肥胖和吸烟相当[<xref ref-type="bibr" rid="hanspub.15441-ref4">4</xref>] 。</p><p>Chu等[<xref ref-type="bibr" rid="hanspub.15441-ref5">5</xref>] 的一项关于MPV与急性心肌梗死(AMI)关系的研究显示，AMI组患者的MPV显著高于稳定型心绞痛(SAP)组患者，且差异有统计学意义，与不稳定型心绞痛(UAP)组患者相比，差异无统计学意义，且MPV增高的程度与AMI后的高死亡率密切相关。Lippi G等[<xref ref-type="bibr" rid="hanspub.15441-ref6">6</xref>] 研究表明，急性冠脉综合征(ACS)患者MPV增高，认为MPV可同以往的心脏标志物一起用于ACS患者的危险分层。国内有研究显示，MPV与冠脉病变严重程度相关，认为MPV越高，冠脉病变越重[<xref ref-type="bibr" rid="hanspub.15441-ref7">7</xref>] 。Sansanayudh N等也同样做了MPV与冠心病的荟萃分析后显示，MPV可作为冠心病的一个危险因素，有早期的预测价值[<xref ref-type="bibr" rid="hanspub.15441-ref8">8</xref>] 。国内学者研究显示，具有冠状动脉疾病高危因素的患者，其MPV较正常人增高，UAP患者的MPV高于SAP患者[<xref ref-type="bibr" rid="hanspub.15441-ref9">9</xref>] 。也有研究显示，MPV是心肌梗死患者PCI术后再灌注损伤和术后半年内发生死亡的一个较强的独立预测因素[<xref ref-type="bibr" rid="hanspub.15441-ref10">10</xref>] 。此外，MPV也是预测稳定型冠心病患者PCI术后再狭窄的一个危险因素[<xref ref-type="bibr" rid="hanspub.15441-ref11">11</xref>] 。心肌梗死患者的MPV与其梗死范围、左心衰和附壁血栓的发生呈正相关[<xref ref-type="bibr" rid="hanspub.15441-ref12">12</xref>] 。</p><p>上述研究表明，临床上检测MPV可能对冠心病的早期诊断及预后判断具有重要意义，MPV增高与临床心血管事件风险增高可能密切相关。</p></sec><sec id="s5"><title>3. FIB与冠心病</title><p>纤维蛋白原(fibrinogen, FIB)是由肝脏合成的一种凝血因子，由三对不同的肽链(Aα, B, γ)组成，它与冠心病的发生存在一定关系，大量研究资料证实，纤维蛋白原是冠心病发病的独立危险因素[<xref ref-type="bibr" rid="hanspub.15441-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.15441-ref14">14</xref>] 。</p><p>FIB导致冠心病风险增加的主要病理机制有：1) FIB的主要功能是参与血液凝固：它与血小板膜上的糖蛋白(GPIIb/IIIa)受体结合，使血小板相互聚集，促进血栓形成[<xref ref-type="bibr" rid="hanspub.15441-ref15">15</xref>] 。2) FIB对血管壁的影响：高水平的FIB通过与内皮细胞膜受体结合，从而破坏血管壁内皮细胞层的完整性，促进动脉粥样斑块形成，动脉血栓发生率增加[<xref ref-type="bibr" rid="hanspub.15441-ref16">16</xref>] 。3) 高水平FIB易使粥样斑块发生溃疡、破裂，从而启动血栓的形成过程[<xref ref-type="bibr" rid="hanspub.15441-ref17">17</xref>] 。4) FIB转变为纤维蛋白后，一方面促进血管内皮细胞、平滑肌细胞合成内皮素，使血管收缩功能增强；另一方面抑制NO合酶，使NO合成减少，继而促进冠脉痉挛，造成血管损伤，促进血栓形成[<xref ref-type="bibr" rid="hanspub.15441-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.15441-ref19">19</xref>] 。FIB升高的冠心病患者，其凝血功能增强，当冠状动脉粥样硬化斑块破裂时，易形成血栓，从而发生心肌梗死。</p><p>在GRIPS研究中，对5239例40~60岁无心血管疾病人群进行5年的跟踪随访，有107人患心肌梗死，其中心肌梗死组FIB水平为(4.2 &#177; 1.0)g/L，非心肌梗死组FIB水平为(3.6 &#177; 0.8)g/L，显示FIB是CHD的一个强预测因素 [<xref ref-type="bibr" rid="hanspub.15441-ref20">20</xref>] 。Lobbes MB等研究显示 [<xref ref-type="bibr" rid="hanspub.15441-ref21">21</xref>] ，纤维蛋白原可以作为冠心病的独立危险因素。有研究显示：调查了176例急性心肌梗死患者，其中有126例患者再次发生心梗或不稳定心绞痛，而这些患者的FIB水平明显高于其他患者，其中死亡者的FIB水平明显高于存活者 [<xref ref-type="bibr" rid="hanspub.15441-ref22">22</xref>] ，故FIB水平影响冠心病患者的预后。国内有研究显示 [<xref ref-type="bibr" rid="hanspub.15441-ref23">23</xref>] ，冠心病组患者FIB水平明显高于对照组。周志建等 [<xref ref-type="bibr" rid="hanspub.15441-ref24">24</xref>] 研究显示，绝大多数AMI组患者FIB半定量测定结果高于正常值，最高达8.4 g/L，与UAP组相比有极显著差异(P &lt; 0.01)。国外随访研究发现，冠心病伴有周围血管疾病患者的FIB水平与心血管事件发生频率有明显的线性关系，因此推断FIB可作为冠心病死亡率的独立危险因素之一 [<xref ref-type="bibr" rid="hanspub.15441-ref25">25</xref>] 。</p><p>国外又有部分研究发现，个体基因型差异可导致FIB水平的差异，可能与心血管风险无关，所以很难确定FIB在冠心病发病机制中的最终地位 [<xref ref-type="bibr" rid="hanspub.15441-ref26">26</xref>] 。国内也有研究显示，FIB β-148gC/T基因多态性位点的表达可以影响FIB的水平，C等位基因可能是冠心病发病的一个危险因素，可能是造成血浆FIB浓度升高的重要原因之一 [<xref ref-type="bibr" rid="hanspub.15441-ref27">27</xref>] 。</p></sec><sec id="s6"><title>4. UA与冠心病</title><p>尿酸(uric acid, UA)是人体内嘌呤代谢的最终产物，来自细胞代谢核酸的分解和部分嘌呤类化合物的分解，约2/3经肾脏排泄，其余则由肠道排出。当尿酸排泄障碍或生成过多时则导致高尿酸血症。</p><p>Gertler [<xref ref-type="bibr" rid="hanspub.15441-ref28">28</xref>] 首次提出尿酸与心血管疾病具有相关性，随后在这方面的研究逐渐增多。NHANES I中心对于5926名年龄在25~74岁的人群进行了16.4年的追踪随访，结果显示，血尿酸每增高59.5 umol/L，女性发生冠心病的风险率增加48%，认为血尿酸是女性冠心病死亡的独立危险因素。另有研究显示，血尿酸不是男性发生冠心病的独立危险因素，但与冠心病相关[<xref ref-type="bibr" rid="hanspub.15441-ref29">29</xref>] 。随后，该中心进行了代称为NHANES III的临床研究显示：当血尿酸水平高于357 umol/l时，血尿酸也可以作为冠状动脉疾病发生的独立危险因素。另有研究发现，高尿酸血症使心血管病患者的死亡率增加[<xref ref-type="bibr" rid="hanspub.15441-ref30">30</xref>] 。Bickel等[<xref ref-type="bibr" rid="hanspub.15441-ref31">31</xref>] 研究了1071例冠心病患者的血尿酸水平与预后的关系，经随访2.2年，结果显示：血尿酸升高是冠心病患者总死亡率的独立危险因素之一。临床及流行病学研究显示高尿酸血症和冠心病的主要危险因素(如高血压、糖尿病、血脂代谢紊乱、肥胖等)之间存在着复杂的相互关系，认为血尿酸水平升高可能仅仅是与冠心病主要危险因素相伴随的一种现象[<xref ref-type="bibr" rid="hanspub.15441-ref32">32</xref>] 。在Framingham心脏研究中，在调整了糖尿病、血压、血脂、吸烟等因素后,尿酸与心血管系统疾病及心源性猝死之间不存在有意义的关系[<xref ref-type="bibr" rid="hanspub.15441-ref33">33</xref>] ，上述研究未能找到尿酸与冠心病的相关性。</p><p>高尿酸血症可能通过以下病理生理机制参与冠心病的发生、发展过程：1) 尿酸对血管内皮细胞的损伤[<xref ref-type="bibr" rid="hanspub.15441-ref34">34</xref>] ：尿酸在血液中物理溶解度很低，高尿酸血症时尿酸微结晶容易析出，尿酸盐易沉积于血管壁，促进血管平滑肌细胞增殖；尿酸增高可激活肾素-血管紧张素系统，从而抑制NO合成，诱发内皮细胞功能异常等。2) 尿酸参与许多炎性介质的合成(如白细胞介素，C反应蛋白等)，间接作用于血管壁，导致心血管事件的发生[<xref ref-type="bibr" rid="hanspub.15441-ref35">35</xref>] 。3) 尿酸可引起血小板激活、粘附及聚集，但也有部分研究持相反观点，认为高尿酸血症不会引起血小板的这些变化[<xref ref-type="bibr" rid="hanspub.15441-ref36">36</xref>] ，与冠心病无相关性。4) 高尿酸血症可通过低密度脂蛋白氧化及脂质过氧化，损伤血管内皮细胞，促进血管平滑肌细胞及内膜增生，导致内皮细胞脱落和血小板粘附、聚集等[<xref ref-type="bibr" rid="hanspub.15441-ref37">37</xref>] 。5) 血尿酸升高加重患者脂代谢紊乱并诱发炎症因子hs-CRP的产生，二者与病情的严重程度有关，是心血管事件的强预测因素[<xref ref-type="bibr" rid="hanspub.15441-ref38">38</xref>] 。血尿酸在冠状动脉疾病的发生、发展及预后方面扮演了重要角色，随着病情的加重血尿酸逐渐增高，是反映冠脉病变严重程度的一个重要指标。因此，在冠状动脉疾病的防治上，我们除了要控制吸烟、高血压、糖尿病等因素外，对于尿酸的控制尤为重要。对血尿酸水平升高的人群应控制高嘌呤食物以减少尿酸形成。治疗上应用促尿酸排泄的药物，从而防治和减少心血管事件的发生。</p><p>综上所述，认为MPV、FIB、UA可作为临床冠心病的早期预测指标，可能在一定程度上评估冠状动脉病变的程度。联合检测三者时，有可能提高其对冠心病的早期诊断及冠状动脉病变严重程度的预测价值，为冠心病的诊治及预后提供新的思路。</p></sec><sec id="s7"><title>文章引用</title><p>贾 梅,刘志跃,杜秀丽, (2015) MPV、FIB、UA水平与冠心病的关系及研究进展Progress and Relationship between Level of MPV, FIB, UA and Coronary Heart Disease. 临床医学进展,02,89-94. doi: 10.12677/ACM.2015.52016</p></sec><sec id="s8"><title>参考文献 (References)</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.15441-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">蔡宗群, 郭舜奇, 郭旭武等 (2014) 急性心肌梗死患者血小板平均体积与临床并发症的相关性. 临床心血管病杂志, 30, 138-141.</mixed-citation></ref><ref id="hanspub.15441-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Slavka, G., Perkmann, T., Haslacher, H., et al. (2011) Mean platelet volume may represent a predictive parameter for overall vascular mortality and ischemic heart disease. Arteriosclerosis, Thrombosis, and Vas-cular Biology, 31, 1215- 1218.</mixed-citation></ref><ref id="hanspub.15441-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Jennings, L.K. (2009) Role of platelets in atherothrombosis. American Journal of Cardiology, 103, 4A-10A.</mixed-citation></ref><ref id="hanspub.15441-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Khode, V., Sindhur, J., Kanbur, D., et al. (2012) Mean platelet volume and other platelet volume indices in patients with stable coronary artery disease and acute myocardial infarction: A case control study. Journal of Cardiovascular Disease Research, 3, 272-275.</mixed-citation></ref><ref id="hanspub.15441-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Chu, S.G., Becker, R.C., Berger, P.B., et al. (2010) Mean platelet volume as a predictor of cardiovascular risk: A systematic review and meta-analysis. Journal of Thrombosis and Haemostasis, 8, 148-156.</mixed-citation></ref><ref id="hanspub.15441-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Lippi, G., Filippozzi, L., Salvagno, G.L., et al. (2009) Increased mean platelet volume in patients with acute coronary syndromes. Archives of Pathology Laboratory Medicine, 133, 1441-1443.</mixed-citation></ref><ref id="hanspub.15441-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">许文亮, 武越, 惠波等 (2012) 冠心病患者血小板平均体积的变化及相关因素研究. 中国循环杂志, 27, 262-265.</mixed-citation></ref><ref id="hanspub.15441-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Sansanayudh, N., Anothaisintawee, T., Muntham, D., et al. (2014) Mean platelet volume and coronary artery disease: A systematic review and meta-analysis. International Journal of Cardiology, 175, 433-440.</mixed-citation></ref><ref id="hanspub.15441-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Coban, E., Ozdogan, M., Yazicioglu, G., et al. (2005) The mean platelet volumein patients with obesity. International Journal of Clinical Practice, 59, 981-982.</mixed-citation></ref><ref id="hanspub.15441-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Huczek, Z., Kochman, J., Filipiak, K.J., et al. (2005) Mean platelet volum on admission predicts impaired reperfusion and long-termmortal-I tyin acutemyocardial infarction treated with primary percutaneous coronary intervention. Journal of the American College of Cardiology, 46, 284-290.</mixed-citation></ref><ref id="hanspub.15441-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Yang, A., Pizzulli, L. and Lüderitz, B. (2006) Mean platelet volume as marker of restenosis after percu-taneous transluminal coronary angioplasty in patients with stable and unstable angina pectoris. Thrombosis Research, 117, 371-377.</mixed-citation></ref><ref id="hanspub.15441-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Yilmaz, M.B., Akin, Y., Biyikoglu, S.F., Guray, U., Kisacik, H.L. and Korkmaz, S. (2004) Left ventricular thombosis is associated with increased mean platelet volume in patients with dilated cardiomyopathy and sinus rhythm. Acta Cardiologica, 59, 41-45.</mixed-citation></ref><ref id="hanspub.15441-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">de Willige, S.U., Standeven, K.F., Philippou1, H. and Ariëns, R.A.S. (2009) The pleiotropic role of the fibrinogen γ’ chain in hemostasis. Blood, 114, 3994-4001.</mixed-citation></ref><ref id="hanspub.15441-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Keenig, W. (1995) Recent progress in the clinical aspects of fibrinogen. European Heart Journal, 16, 54-59.</mixed-citation></ref><ref id="hanspub.15441-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">竟雪莹, 祖磊, 桑更生 (2013) 慢性阻塞性肺疾病患者血浆纤维蛋白原与冠心病的相关性研究. 中华全科医学, 10, 1540-1541.</mixed-citation></ref><ref id="hanspub.15441-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Lominadze, D., Dean, W.L., Tyagi, S.C. and Roberts, A.M. (2010) Mechanisms of fibrinogen-induced microvascular dysfunction during cardiovascular disease. Acta Physiologica, 198, 1-13.</mixed-citation></ref><ref id="hanspub.15441-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Fragoso-Lona, J.M., Ramírez-Bello, J., Cruz-Robles, D., Pérez-Méndez, O., de la Peña, A. and Vargas-Alarcón, G. (2009) Pro-inflammatory and anti-inflammatory markers in coronary artery disease and acute ischemic coronary syndrome. Archivos de Cardiología de México, 79, 54-62.</mixed-citation></ref><ref id="hanspub.15441-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Pacilli, A., De Cosmo, S., Trischitta, V. and Bacci, S. (2013) Role of relationship between HbA1c, fibrinogen and HDL-cholesterol on cardiovascular disease in patients with type 2 diabetes mellitus. Atherosclerosis, 228, 247-248.</mixed-citation></ref><ref id="hanspub.15441-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">王雪青 (1996) 纤维蛋白(原)在动脉粥样硬化发病中的作用及机制. 生理科学进展, 3, 245-248.</mixed-citation></ref><ref id="hanspub.15441-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Stubbs, M.T., Oschkinat, H., Mayr, I., Huber, R., Angliker, H., Stone, S.R. and Bode, W. (1992) The interaction of thrombin with fibrinogen. A structural basis for its specificity. European Journal of Biochemistry, 206, 187-195.</mixed-citation></ref><ref id="hanspub.15441-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Lobbes, M.B.I., Kooi, M.E., Lutgens, E., Ruiters, A.W., Passos, V.L., Braat, S.H.J.G., et al. (2010) Leukocyte counts, myeloperoxidase, and pregnancy-associated plasma protein a as biomarkers for cardiovascular disease: Towards a multi-biomarker approach. International Journal of Vascular Medicine, 2010, Article ID: 726207.</mixed-citation></ref><ref id="hanspub.15441-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Kannel, W.B., Wolf, P.A., Castelli, W.P. and D’Agostino, R.B. (1987) Fibrinogen and risk of cardiovascular disease. The Framingham study. Journal of the American Medical Association, 258, 1183-1186.</mixed-citation></ref><ref id="hanspub.15441-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">胡叶, 智永超, 张芝晶, 刘永华, 王心杰 (2010) 冠心病患者血清纤维蛋白原、高敏C反应蛋白与粥样斑块不稳定性的关系研究. 中国当代医药, 16, 18-20.</mixed-citation></ref><ref id="hanspub.15441-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">周志健, 代志行, 李晓云, 常晓慧, 李晨玲, 高荣 (2002) 冠心病人止凝血分子标志物指标异常的研究. 中国微循环, 3, 161-162.</mixed-citation></ref><ref id="hanspub.15441-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Bosevski, M., Kostoska, S., Tosev, S. and Borozanov, V. (2006) Usefulness of D-Dimers and fibrinogen plasma determination in patients with polyvascular disease. Angiologii͡a i sosudistai͡a khirurgii͡a, 12, 9-15.</mixed-citation></ref><ref id="hanspub.15441-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Tousoulis, D., Papageorgiou, N., Androulakis, E., Briasoulis, A., Antoniades, C. and Stefanadis, C. (2011) Fibrinogen and cardiovascular disease: Genetics and biomarkers. Blood Reviews, 25, 239-245.</mixed-citation></ref><ref id="hanspub.15441-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">周明权 (2012) 冠心病患者凝血四项及纤维蛋白原多态性分析. 中国实用医药, 5, 70-71.</mixed-citation></ref><ref id="hanspub.15441-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Gertler, M.M., Garn, S.M. and Levine, S.A. (2012) Serum uric acid in relation to age and physique in health and in coronary heart disease. Annals of Internal Medicine, 34, 1421-1431.</mixed-citation></ref><ref id="hanspub.15441-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Fang, J. and Alderman, M.H. (2000) Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National health and nutrition examination survey. Journal of the American Medical Association, 283, 2404-2410.</mixed-citation></ref><ref id="hanspub.15441-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Krishnan, E., Pandya, B.J., Chung, L., et al. (2011) Hyperuricemia and the risk for subclinical coronary atherosclerosis-data from a prospective observational cohort study. Arthritis Research Therapy, 13, R66.</mixed-citation></ref><ref id="hanspub.15441-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">党爱民, 刘国仗 (2003) 尿酸和心血管事件. 中华心血管病杂志, 6, 478-480.</mixed-citation></ref><ref id="hanspub.15441-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Feig, D.I., Kang, D.H. and Johnson, R.J. (2008) Uric acid and cardiovascular risk. The New England Journal of Medicine, 359, 1811-1821.</mixed-citation></ref><ref id="hanspub.15441-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Culleton, B.F., Larson, M.G., Kannel, W.B. and Levy, D. (1999) Serum uric acid and risk for cardiovascular disease and death: The Framingham heart study. Annals of Internal Medicine, 131, 7-13.</mixed-citation></ref><ref id="hanspub.15441-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Kanbay, M., Sánchez-Lozada, L.G., Franco, M., Madero, M., Solak, Y., Rodriguez-Iturbe, B., et al. (2011) Microvascular disease and its role in the brain and cardiovascular system: A potential role for uric acid as a cardiorenal toxin. Nephrology Dialysis Transplantation, 26, 430-437.</mixed-citation></ref><ref id="hanspub.15441-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Zapolski, T., Waciński, P., Kondracki, B., Rychta, E., Buraczyńska, M.J. and Wysokiński, A. (2011) Uric acid as a link between renal dysfunction and both pro-inflammatory and prothrombotic state in patients with metabolic syndrome and coronary artery disease. Kardiologia Polska, 69, 319-326.</mixed-citation></ref><ref id="hanspub.15441-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Edwards, N.L. (2009) The role of hyperuricemia in vascular disorders. Current Opinion in Rheumatology, 21, 132-137.</mixed-citation></ref><ref id="hanspub.15441-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Ruggiero, C., Cherubini, A., Ble, A., Bos, A.J., Maggio, M., Dixit, V.D., et al. (2006) Uric acid and inflammatory markers. European Heart Journal, 27, 1174-1181.</mixed-citation></ref><ref id="hanspub.15441-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">栾雪静, 李世伟 (2010) 超敏C反应蛋白和血尿酸与心血管疾病的关系. 现代预防医学, 14, 2778-2779.</mixed-citation></ref></ref-list></back></article>